Ability of anti-α3(V) antibodies to slow WT/PyMT tumour growth suggests α3(V) as a potential target for therapeutic treatments of human tumours in which α3(V)-GPC1 interactions contribute to cell growth. The gene discussed is GPC1; the disease is neoplasm.